Aberdeen Group plc Trims Position in Tenet Healthcare Corporation $THC
Aberdeen Group plc significantly reduced its stake in Tenet Healthcare Corporation (NYSE:THC) by 37.5% in the third quarter, selling 22,372 shares. Despite this reduction, analysts maintain a broadly bullish outlook, with a consensus "Moderate Buy" rating and a target price of $247.67. Tenet Healthcare recently surpassed quarterly earnings estimates, reporting $4.70 EPS and $5.53 billion in revenue, and set strong FY2026 guidance.
THC: Leerink Partners Raises Price Target for Tenet Healthcare
Leerink Partners has reaffirmed its "Outperform" rating for Tenet Healthcare (THC) and increased its price target from $255.00 to $264.00, indicating a positive outlook for the company's future growth. This is part of a trend of favorable analyst ratings and increased price targets from various firms such as Truist Securities, Guggenheim, Barclays, Keybanc, and UBS. While analysts project an average upside of 8.71% from the current price, GuruFocus estimates a potential downside of 37.11% based on its GF Value fair value assessment.
The Analyst Verdict: Tenet Healthcare In The Eyes Of 12 Experts
Over the past three months, 12 analysts have provided diverse ratings for Tenet Healthcare (NYSE: THC), with 6 bullish and 6 somewhat bullish assessments. The average price target has increased to $259.25, up 5.28% from the previous average of $246.25, with a high estimate of $288.00 and a low of $229.00. The article also highlights Tenet Healthcare's strong financial health, including impressive net margin, return on equity, and return on assets, despite a high debt-to-equity ratio.
Hospital giant plans major redevelopment in West Palm Beach
Tenet Healthcare's Palm Beach Health Network and Easton Street Capital have announced plans for a major redevelopment in West Palm Beach, including a new Good Samaritan Medical Center. This project aims to construct a new hospital facility, which will then free up a prime waterfront site for residential development. The initiative is set to significantly transform a key area of West Palm Beach.
Vanguard Group Inc. Has $1.83 Billion Stock Position in Tenet Healthcare Corporation $THC
Vanguard Group Inc. recently trimmed its stake in Tenet Healthcare Corporation by 4.8% but still holds 9,009,590 shares, valued at approximately $1.83 billion, representing about 10.25% of the company. Tenet Healthcare exceeded Q3 earnings expectations and provided strong FY2026 guidance, leading analysts to raise price targets, with the stock currently holding a "Moderate Buy" consensus rating. Corporate insiders hold a small percentage, while institutional investors own the majority, and one director recently sold shares.
The 5 Most Interesting Analyst Questions From Tenet Healthcare's Q4 Earnings Call
Tenet Healthcare reported strong Q4 results for CY2025, exceeding analyst expectations for revenue, EPS, and adjusted EBITDA, primarily driven by its ambulatory surgical center business and disciplined expense management. The article highlights key analyst questions from the earnings call, focusing on hospital volumes, structural expense management, admission growth guidance, cost initiatives, and the sustainability of margin improvement. Management addressed these points, attributing some results to a weaker respiratory season but emphasizing the impact of capital investments, technology adoption, and ongoing efficiency efforts contributing to future growth and cost savings.
THC: Truist Securities Raises Price Target for Tenet Healthcare
Truist Securities has raised its price target for Tenet Healthcare (THC) to $270.00 from $240.00, while maintaining a "Buy" rating. This increase reflects a general positive sentiment among analysts, with several other firms also recently upgrading Tenet's price targets. Despite the positive analyst outlook, GuruFocus's estimated GF Value suggests a potential downside from the current stock price.
Tenet Healthcare (NYSE:THC) Price Target Raised to $270.00 at Truist Financial
Truist Financial has increased its price target for Tenet Healthcare (NYSE:THC) to $270.00 from $240.00, maintaining a "buy" rating, which suggests a 16% upside. This follows Tenet's strong fourth-quarter earnings, where it surpassed analyst expectations with $4.70 EPS on an 8.9% revenue increase, and provided optimistic FY2026 guidance. The company currently holds a "Moderate Buy" consensus rating among analysts, with a target price of $246.71.
Tenet Healthcare (THC) Is Up 19.8% After Strong Q4 Beat, Higher 2026 Guidance And Buybacks
Tenet Healthcare (THC) saw a 19.8% stock increase following its strong Q4 2025 earnings beat, improved 2026 guidance, and significant share repurchases. The company's strategy focuses on higher-margin ambulatory surgery growth and cost-efficiency, reinforced by its recent financial performance and an anticipated US$2.61–US$2.84 billion net income for 2026. While the stock has risen, the company's high debt load and insider selling remain factors for investors to consider.
Caprock Group LLC Invests $1.63 Million in Tenet Healthcare Corporation $THC
Caprock Group LLC has acquired a new stake of 8,042 shares in Tenet Healthcare Corporation, valued at approximately $1.63 million in the third quarter. This investment comes as Tenet Healthcare reported strong Q3 earnings, surpassing analyst expectations with $4.70 EPS and $5.53 billion in revenue, and provided optimistic FY2026 EPS guidance. Wall Street analysts maintain a "Moderate Buy" consensus rating for the stock, with an average target price of $242.82.
ING Groep NV Sells 24,400 Shares of Tenet Healthcare Corporation $THC
ING Groep NV has significantly reduced its stake in Tenet Healthcare Corporation (NYSE:THC) by selling 24,400 shares, decreasing its position by 64.7% to 13,300 shares worth $2.7 million. This comes as Tenet Healthcare reported strong quarterly earnings, beating analyst estimates and raising its full-year 2026 guidance, leading to a "Moderate Buy" consensus rating among analysts with a target price near $242.82. Other institutional investors have also adjusted their holdings, while insider Nadja West sold 2,178 shares.
Krilogy Financial LLC Buys Shares of 5,714 Tenet Healthcare Corporation $THC
Krilogy Financial LLC acquired a new stake of 5,714 shares in Tenet Healthcare (THC) during Q3, valued at approximately $1.19 million. Tenet Healthcare's Q4 earnings surpassed estimates, and the company raised its FY2026 guidance, leading to analyst price target increases and a "Moderate Buy" consensus. However, the company faces a projected $250 million headwind due to the loss of ACA subsidies, and analysts are monitoring potential pressure on 2026 EBITDA margins.
Barclays Raises Price Target for Tenet Healthcare (THC) to $257
Barclays analyst Andrew Mok has increased the price target for Tenet Healthcare (THC) from $240 to $257, while maintaining an "Overweight" rating. This follows a trend of positive revisions from other analysts, indicating strong market confidence in the company, despite GuruFocus' estimated fair value suggesting a potential downside. Tenet Healthcare operates acute and specialty hospitals and ambulatory surgery centers primarily in the Southern US, also providing revenue cycle management solutions through its Conifer segment.
Guggenheim raises Tenet Healthcare stock price target on strong 2026 guidance
Guggenheim has increased its price target for Tenet Healthcare to $271.00 from $257.00, maintaining a Buy rating after the company's strong fourth-quarter earnings and higher-than-expected 2026 guidance. The healthcare provider's outlook projects approximately 10% core EBITDA growth from its Hospital segment, despite anticipated headwinds in later years. Other firms like KeyBanc and Jefferies also raised their price targets, signaling positive analyst sentiment.
UBS Raises Price Target for Tenet Healthcare (THC) to $288 | THC Stock News
UBS has re-affirmed its "Buy" rating for Tenet Healthcare (THC) and increased its price target to $288, up from $260, indicating strong confidence in the stock's future. This adjustment aligns with a generally positive sentiment from several analysts who have recently raised their price targets for the Dallas-based healthcare services organization. Despite the positive analyst outlook, GuruFocus's GF Value estimates a potential downside for THC, suggesting a divergence in valuation perspectives.
Tenet Healthcare Corporation (NYSE:THC) Q4 2025 Earnings Call Transcript
Tenet Healthcare Corporation (NYSE:THC) reported strong Q4 and full-year 2025 earnings, exceeding expectations with $21.3 billion in net operating revenues and $4.57 billion in consolidated adjusted EBITDA for the full year. The company's USPI segment continued robust growth, and the Hospital segment also showed significant improvement. For 2026, Tenet projects adjusted EBITDA between $4.485 billion and $4.785 billion, anticipating continued demand and strategic investments, despite headwinds from expiring enhanced premium tax credits.
Tenet Healthcare stock price target raised to $250 from $225 at KeyBanc
KeyBanc has increased its price target for Tenet Healthcare (NYSE:THC) to $250 from $225, reiterating an Overweight rating. This decision follows Tenet's strong fourth-quarter results and optimistic 2026 guidance, which led to a 17% surge in the company's shares. KeyBanc highlighted the company's potential for significant efficiency gains and elevated healthcare services utilization as key drivers for long-term value.
THC Q4 Deep Dive: Tech-Driven Efficiency and Ambulatory Expansion Offset Exchange Headwinds
Tenet Healthcare (THC) reported strong Q4 CY2025 results, beating revenue and adjusted EPS expectations, driven by growth in its ambulatory surgical center business, disciplined expense management, and a favorable payer mix. Despite projected headwinds from the phase-out of enhanced premium tax credits, the company plans to offset these impacts through continued technology investments, ambulatory expansion, and structural cost initiatives. Management is focused on operational efficiencies, strategic M&A, and leveraging its Conifer unit to support future growth and navigate a challenging reimbursement environment.
Tenet Healthcare Beats Q4 Earnings: But 2026 EBITDA Margin May Decline
Tenet Healthcare (THC) reported strong fourth-quarter 2025 earnings, exceeding analyst expectations for EPS and revenue, driven by higher same-facility revenues and a favorable payer mix. Despite this, the company projects a potential decline in its adjusted EBITDA margin for 2026, even as net operating revenues are expected to increase. The article also provides financial details for THC's segments and an outlook for the coming year, alongside performance summaries of other medical companies.
Tenet Looks Likely To Fend Off Many Upcoming Headwinds
Tenet Healthcare has successfully revitalized its operations since late 2017 by divesting underperforming assets, improving governance, and enhancing efficiency. The company is strategically focused on expanding its high-margin ambulatory surgery business, which offers better growth prospects than its acute hospital operations. These efforts have led to consistent returns on invested capital that exceed the weighted average cost of capital, positioning Tenet to address future challenges effectively.
Tenet Healthcare shares steady after strong Q4, upbeat 2026 outlook
Tenet Healthcare reported a strong Q4 2025 with net operating revenues reaching $5.527 billion and adjusted diluted EPS rising 36.6% to $4.70. The company also provided an upbeat 2026 outlook, projecting net operating revenues between $21.5 billion and $22.3 billion. Despite remaining below its 52-week high, Tenet's shares have shown resilience and a positive longer-term trend.
Tenet Healthcare Quarterly Profit Surges As Hospital, Surgery Demand Grows
Tenet Healthcare (NYSE: THC) reported strong fourth-quarter results for 2025, with sales up 8.9% year-over-year to $5.527 billion and adjusted earnings per share of $4.70, exceeding analyst estimates. The growth was driven by increased demand for hospital and ambulatory surgical services, favorable payer mix, and higher acuity cases. The company provided an optimistic outlook for 2026, forecasting continued revenue growth and adjusted EBITDA between $4.485 billion and $4.785 billion, reflecting sustained demand and strategic execution.
Tenet Healthcare stock hits all-time high of 222.83 USD
Tenet Healthcare Corporation's stock has reached an all-time high of $222.83, marking a 39.05% increase over the past year. The company's strong financial performance, aggressive share buybacks, and impressive fourth-quarter 2025 results, which exceeded earnings and revenue expectations, have contributed to this milestone. Analysts maintain a "Strong Buy" consensus, with InvestingPro Fair Value suggesting the stock is slightly undervalued despite its recent surge.
Tenet Healthcare (NYSE:THC) Surprises With Q4 CY2025 Sales
Tenet Healthcare (NYSE:THC) reported strong Q4 CY2025 results, exceeding revenue and adjusted EPS expectations with sales up 9% year-on-year to $5.53 billion and adjusted EPS of $4.70. While full-year revenue guidance for FY2026 was slightly below analyst estimates, adjusted EPS guidance for FY2026 surpassed expectations. The company demonstrated solid long-term profitability and shareholder value through EPS growth and share buybacks.
Tenet Healthcare Corp (NYSE:THC) Reports Strong Q4 2025 Earnings Beat and Provides 2026 Outlook
Tenet Healthcare Corp (NYSE:THC) reported robust financial results for Q4 and full year 2025, surpassing analyst expectations with adjusted EPS of $4.70 and revenue of $5.53 billion. The company's performance was driven by strong growth in its ambulatory care and hospital operations segments, leading to positive market reception. Tenet also provided a 2026 outlook with projected revenues between $21.5 billion and $22.3 billion and adjusted EPS between $16.19 and $18.47, signaling steady growth and continued focus on shareholder returns through free cash flow.
Guggenheim Keeps Their Buy Rating on Tenet Healthcare (THC)
Guggenheim analyst Jason Cassorla has maintained a Buy rating on Tenet Healthcare (THC) with a price target of $257.00. This comes despite a recent downgrade from TipRanks – xAI to Hold. The company reported quarterly revenue of $5.29 billion and a net profit of $342 million for the quarter ending September 30, though corporate insider sentiment is reported as negative due to increased selling activity.
Tenet Healthcare Corporation Reports Strong Q4 and FY 2025 Results
Tenet Healthcare Corporation announced strong financial results for Q4 and the full year 2025, with significant growth in net income and Adjusted EBITDA. The company highlighted robust performance in its Ambulatory Care and Hospital Operations segments, along with strategic initiatives including share repurchases and debt refinancing. Management expressed confidence in continued demand and provided a positive outlook for 2026, projecting increased Adjusted EBITDA, revenues, and free cash flow.
Tenet: Q4 Earnings Snapshot
Tenet Healthcare Corp. reported strong fourth-quarter earnings, with net income of $371 million, or $4.22 per share, surpassing analyst expectations. Adjusted earnings per share reached $4.70, significantly higher than the estimated $4.08. The hospital operator's revenue also beat forecasts, coming in at $5.53 billion against an expected $5.45 billion.
Tenet Healthcare Corp (NYSE:THC) Presents a Value Investment Case with Strong Profitability
Tenet Healthcare Corp (NYSE:THC) appears to be a strong value investment opportunity, marked by a high Valuation Rating of 9 out of 10 and a Profitability Rating of 9 out of 10. The company boasts competitive P/E ratios and impressive margins, indicating a potentially undervalued stock with robust financial performance. While its financial health shows a moderate rating due to elevated debt, Tenet Healthcare's strong earnings growth and ability to create value for shareholders suggest a compelling case for value investors.
Will Tenet (THC) Beat Estimates Again in Its Next Earnings Report?
Tenet Healthcare (THC) is poised for another earnings beat according to Zacks Equity Research, due to its history of surpassing estimates and a positive Zacks Earnings ESP of +2.72%. Combined with a Zacks Rank #3 (Hold), this indicates a nearly 70% chance of a positive surprise in its upcoming report, expected around February 11, 2026. The company has a strong record, with its average surprise for the last two quarters being 26.33%.
Lawsuit Investigation: Tenet Healthcare Privacy Violations?
Attorneys are investigating Tenet Healthcare Corporation for potential privacy violations, specifically alleging that the company shared sensitive patient information with Facebook and Google via tracking tools on its hospital websites. The investigation focuses on whether Tenet unlawfully transmitted medical data, such as symptoms and treatments, to third parties. If successful, a class action lawsuit could provide compensation to affected patients and prevent future data-sharing issues.
Tenet Healthcare (THC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Tenet Healthcare (THC) is expected to announce a year-over-year increase in earnings and higher revenues for the quarter ending December 2025, with results to be released on February 11. The hospital operator's earnings per share are projected to grow by 18.6% to $4.08, and revenues by 7.4% to $5.45 billion. Analysts have recently become more bullish, with a positive Earnings ESP of +2.72% and a Zacks Rank #3 (Hold), suggesting a high probability of beating the consensus EPS estimate.
THC: RBC Capital Raises Price Target to $253, Affirms Outperform Rating | THC Stock News
RBC Capital has reaffirmed its 'Outperform' rating for Tenet Healthcare (THC) and increased its price target from $252.00 to $253.00, signaling continued optimism for the company's stock performance. This adjustment comes amidst other varying analyst ratings and price target changes, with the average analyst target price suggesting an upside of 21.49% from the current price. However, GuruFocus' estimated GF Value indicates a potential downside of 24.73% for THC.
RBC Capital raises Tenet Healthcare stock price target to $253 on strong results
RBC Capital has increased its price target for Tenet Healthcare (NYSE:THC) to $253 from $252, maintaining an Outperform rating. This adjustment follows strong preliminary fourth-quarter results and the firm's view that proceeds from the CommonSpirit Health contract termination offset the lost business. Tenet recently regained full ownership of Conifer Health Solutions and refinanced $2.25 billion in debt.
Tenet Healthcare Details $2.65B Conifer-CommonSpirit Deal, Flags Share Buybacks and AI Push
Tenet Healthcare has announced the closure of an asset sale related to Conifer's revenue-cycle contract with CommonSpirit, valued at $2.65 billion. This deal provides Tenet with full strategic control of Conifer, allowing it to accelerate initiatives in offshoring, automation, and AI. The company plans to prioritize share buybacks, ambulatory M&A, and organic growth, while strengthening its cash flow and maintaining a deleveraged balance sheet.
CommonSpirit to pay Tenet $1.9B in RCM deal
CommonSpirit Health has sold its minority stake in Conifer Health Solutions, Tenet Healthcare Corporation’s revenue cycle management subsidiary, for $1.9 billion. As a result of this deal, CommonSpirit will no longer utilize Tenet's revenue cycle management services. The article also mentions other featured stories related to healthcare.
Tenet regains full ownership of Conifer as CommonSpirit exits
Tenet Healthcare Corporation has reacquired full ownership of its Conifer Health Solutions subsidiary from CommonSpirit Health. The deal involves CommonSpirit making payments of approximately $1.9 billion to Tenet over three years, while Conifer will pay CommonSpirit $540 million to redeem its 23.8% equity stake. Tenet anticipates its Adjusted EBITDA for 2025 to reach the upper end of its guidance and plans to enhance Conifer's revenue cycle management services through investments in AI and automation.
Tenet takes back Conifer in $1.9B CommonSpirit exit, services through 2026
Tenet Healthcare (NYSE: THC) announced it has completed a strategic transaction with CommonSpirit Health, resuming full ownership of its Conifer Health Solutions subsidiary. The deal involves payments totaling approximately $1.9 billion from CommonSpirit to Tenet over three years and eliminates CommonSpirit's equity stake in Conifer. Conifer will continue to support CommonSpirit until the end of 2026, after which it will focus on expanding its technology-enabled services, artificial intelligence, and automation investments.
Tenet (NYSE: THC) eyes top-end 2025 EBITDA, restructures $1.9B CHI deal
Tenet Healthcare Corporation expects its 2025 Adjusted EBITDA to be at the upper end of its $4.47 billion to $4.57 billion guidance range. The company also entered into an Omnibus Agreement with Conifer subsidiaries and CommonSpirit Health (CHI), with CHI agreeing to pay Tenet $1.9 billion in annual installments over three years. This restructuring, including Conifer Health redeeming CHI's equity interest, is anticipated to reduce Tenet’s redeemable non-controlling interest and other liabilities by approximately $885 million and increase additional paid-in capital by about $305 million.
5,532 Shares in Tenet Healthcare Corporation $THC Purchased by Winnow Wealth LLC
Winnow Wealth LLC has acquired a new position of 5,532 shares in Tenet Healthcare Corporation (THC), valued at approximately $1.13 million. Despite recent insider selling totaling $8.73 million by directors like Tammy Romo and Nadja West, analysts maintain a "Moderate Buy" rating with a consensus price target of $233.81 for THC, following the company beating third-quarter earnings estimates. Institutional investors collectively own 95.44% of Tenet Healthcare's stock.
Tenet Healthcare Corporation (THC) Stock Analysis: An Investor’s Guide to Potential 25.9% Upside
Tenet Healthcare Corporation (THC) is presented as an attractive investment in the healthcare sector, highlighted by its 27.36% return on equity and substantial free cash flow. Analyst ratings are overwhelmingly positive with a target price suggesting a 25.90% upside. While technical indicators show some recent downward pressure, the company's strong financial metrics and strategic focus make it a compelling option for growth-oriented investors.
Wealth Enhancement Advisory Services LLC Has $5.54 Million Position in Tenet Healthcare Corporation $THC
Wealth Enhancement Advisory Services LLC significantly increased its stake in Tenet Healthcare Corporation, owning 27,032 shares valued at $5.54 million. This move follows Tenet Healthcare beating its Q3 earnings estimates and issuing strong FY2025 guidance. Analysts have largely maintained a "Moderate Buy" consensus, with several firms raising their price targets for the stock.
Retirement Systems of Alabama Has $33.94 Million Position in Tenet Healthcare Corporation $THC
Retirement Systems of Alabama has reduced its stake in Tenet Healthcare Corporation by 3.9% in the third quarter, now holding 167,178 shares valued at $33.94 million. Despite this, institutional ownership remains high at 95.44%, with other major investors increasing their positions. Tenet Healthcare exceeded Q3 earnings expectations and provided strong FY2025 guidance, leading to a "Moderate Buy" consensus from analysts with an average price target of $233.81.
3,100 Tenet nurses strike for patient safety
Nurses at six Tenet hospitals across California held one-day strikes to protest the corporation's refusal to address concerns about patient care and safe staffing. The 3,100 Tenet nurses, represented by CNA/NNU, are in contract negotiations seeking improvements in staffing, meal and rest breaks, recruitment, retention, and lift teams. They accuse Tenet of prioritizing profits over patient safety, citing specific issues in neonatal intensive care units and overall understaffing.
QRG Capital Management Inc. Sells 13,722 Shares of Tenet Healthcare Corporation $THC
QRG Capital Management Inc. significantly reduced its stake in Tenet Healthcare Corporation (NYSE:THC) by 65.7% in Q3, selling 13,722 shares and retaining 7,156 shares valued at approximately $1.45 million. Despite insider selling totaling $9.25 million over the past 90 days, analysts maintain a "Moderate Buy" consensus rating with a target price of $233.81. The company reported strong Q3 earnings, beating estimates with $3.70 EPS on revenues of $5.29 billion.
Trial begins Friday in lawsuit between Tenet hospitals and Leapfrog Group
A federal trial is set to begin Friday in West Palm Beach between five Tenet Healthcare hospitals and The Leapfrog Group. The hospitals, part of Palm Beach Health Network, are suing Leapfrog over its "D" and "F" safety ratings, claiming they are misleading, inaccurate, and damaging, especially since the hospitals did not participate in Leapfrog's voluntary data submission. Leapfrog denies the allegations, asserting the lawsuit is an attempt to suppress information and that federal data supports their ratings regarding patient harm.
Tenet Healthcare (THC) Valuation Check After Strong Multi Year Total Shareholder Returns
Tenet Healthcare (THC) has shown strong multi-year returns, but its current valuation suggests it may be undervalued. The company's P/E ratio of 12.9x is significantly lower than its estimated fair P/E of 22.7x and below industry averages. A discounted cash flow model also indicates the shares are trading below their fair value, prompting questions about market concerns despite these positive indicators.
Saint Vincent Hospital lists new interim CEO
Saint Vincent Hospital has appointed a new interim CEO. The article is very short and does not provide further details about the new CEO or the hospital's plans. It seems to be a placeholder or broken article from The Worcester Guardian.
Tenet Healthcare (THC) Registers a Bigger Fall Than the Market: Important Facts to Note
Tenet Healthcare (THC) experienced a 2.01% decline in its latest trading session, underperforming the broader market. Despite this short-term dip, the company's shares have risen 1.17% over the last month, and analysts project a significant 17.73% EPS increase for its upcoming earnings report on February 11, 2026. Tenet Healthcare currently holds a Zacks Rank of #3 (Hold) and is trading at a premium compared to its industry's average Forward P/E ratio.
New York State Teachers Retirement System Sells 5,401 Shares of Tenet Healthcare Corporation $THC
New York State Teachers Retirement System reduced its stake in Tenet Healthcare Corporation by 5.5% in the third quarter, selling 5,401 shares and now owning 92,381 shares valued at approximately $18.76 million. Institutional investors collectively own 95.44% of the company's stock. Analysts currently rate Tenet Healthcare as a "Moderate Buy" with a consensus target price of $233.81.
